ORGANIZATION AND BUSINESS (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
	Apr. 06, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
ORGANIZATION AND BUSINESS [Line Items]
Business Development		$ 7,280,000
Net Loss			$ 5,270,483	$ 2,753,642
Cash and Cash Equivalents, at Carrying Value, Total			317,627	$ 844,043	$ 6,306
Accrued Fees and Other Revenue Receivable		1,000,000	$ 105,000,000
First Tranche Amount Receivable After Enrollment Of First Patient In Ophthalmic Trial		500,000
Second Tranche Amount Receivable After Enrollment Of The First Patient In An Ophthalmic Trial		$ 500,000
Description of Equity Ownership Interest			RegeneRx’s ownership interest in ReGenTree is 49% and will be reduced to 42% when the clinical study report is filed for the Phase 3 dry eye clinical trial. Based on when, and if, certain additional development milestones are achieved in the U.S. with RGN-259, our equity ownership may be incrementally reduced to between 42% and 25%, with 25% being the final equity ownership upon approval of an NDA for Dry Eye Syndrome in the U.S. In the event the ReGenTree entity is acquired, or there is a change of control that occurs following achievement of an NDA, RegeneRx shall be entitled to 40% of all change of control proceeds paid or payable and will forgo any future royalties.
Subsequent Event [Member]
ORGANIZATION AND BUSINESS [Line Items]
Proceeds from Contributions from Affiliates	$ 250,000